Navigation Links
Accelovance Expands Oncology Leadership with the Addition of Ralph Boccia, MD as Oncology Medical Director
Date:3/1/2013

ROCKVILLE, Md., March 1, 2013 /PRNewswire-USNewswire/ -- Accelovance announces the addition of Ralph Boccia , MD, FACP as the Oncology Medical Director.  The addition of Dr. Boccia is a strong compliment to the oncology strength the Maryland-based CRO that caters to biotech and small/mid pharma Sponsors.  In addition to his responsibilities at Accelovance, Dr. Boccia is a founder and the Medical Director of the Center for Cancer and Blood Disorders.  He also is an active Clinical Associate Professor of Medicine at Georgetown University and consulting Medical Director of the International Oncology Network (ION) Clinical Research Program.

Accelovance offers innovative clinical solutions focused on oncology that accelerate study start up timelines; existing partnerships with leading oncology academic institutions and improved  access to target patient populations that in turn control study budgets.  Such solutions are ideal for Phase I/II and ClinPharm studies where speed, quality and cost-effectiveness are critical to support Sponsor business goals. This model mirrors the highly successful approach utilized by Accelovance with their vaccine and infectious disease programs.

"We are thrilled to have a recognized leader in medical oncology and hematology, Dr. Ralph V. Boccia , join our organization.  His 31 years of practice and clinical research are an asset to the clients we serve as we help define patient populations, study protocols and program approaches," remarked Stephen J. Trevisan , Accelovance President and Chief Executive Officer. "His addition complements our oncology experienced CRO team that has had tremendous growth over the last 12 months in clinical operations, project management and data management."

"It is a unique opportunity to join a forward-thinking, patient-centric clinical services company like Accelovance. This team's commitment to advancing the novel oncology therapies has real value to Sponsors.  We are actively talking to companies with promising technology and it is quite exciting," commented Ralph V. Boccia , MD, FACP.  He is a board-certified Medical Oncologist with specialties in internal medicine and hematology.  Dr. Boccia earned his medical degree at the University of Minnesota and completed training in internal medicine at UCLA-affiliated hospitals.  His hematology, oncology and bone marrow transplant fellowships were completed at the combined UCLA-VA program at the National Cancer Institute (NCI) at the National Institutes of Health in Bethesda, Maryland.

Headquartered in Rockville, Maryland, Accelovance is a privately held company that has developed a unique operational approach for delivering quality, on time, and cost effective clinical studies.  The company was recognized as "Best CRO" with consecutive Industry Excellence awards in 2009, 2010 and 2011. The Company tailors its offering of full CRO, Clinical Sites, Patient Recruitment, and Call Center to present a clinical solution that meets a Sponsor's needs.  Accelovance has a 100% owned subsidiary providing CRO services in China.  These capabilities can assist clients with global development programs or product registration in China, the fastest growing pharmaceutical market in the world.  Additionally, Accelovance offers six (6) wholly-owned, research-dedicated clinical sites to Sponsors and CROs that bring greater control, predictability, and quality assurance to therapeutically aligned studies.

For more information, visit the company's website at http://www.accelovance.com

Media Contact:
Garrett D. Smith
Phone: 240.238.4914
gsmith@accelovance.com


'/>"/>
SOURCE Accelovance
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amedica Expands Patent Portfolio with Proprietary Silicon Nitride Total Disc Implant to Treat Neck and Back Pain
2. Cephasonics Expands Market Presence, Enters Ultrasound Research Market with Large-Channel-Count Modular System Offering Up to 4,096 Channels
3. Hyland Software Expands its Partnership with Nuance Communications to Improve Efficient Care Models at Healthcare Facilities
4. DSI Renal Expands Georgia Presence with Conyers and Kennesaw Dialysis Clinics
5. Cogmedix Expands To Support Laser Based Medical Devices
6. Heraeus Expands Its Venus White Line of Whitening Maintenance and Oral Care Products
7. CryoLife Expands Stock Repurchase Program
8. Modulus Expands Offerings with Patch Design and Manufacturing
9. BioElectronics Expands to the Czech & Slovak Republic
10. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
11. Marken Expands Regulatory And Technical Excellence In Logistics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... Plano, TX (PRWEB) , ... June 24, 2016 , ... ... taking part in Genome magazine’s Code Talker Award, an essay contest in which patients ... for an award to be presented at the 2016 National Society of Genetic Counselors ...
(Date:6/24/2016)... ... 2016 , ... Strategic Capital Partners, LLC (SCP) in concert ... capital for emerging technology companies. SCP has delivered investment events and professional ... than a million dollars of capital investment for five companies. The ...
Breaking Medicine News(10 mins):